Clinical-Microbiological Discordance and Delayed Mortality in OXA-48/ESBL-Producing Proteus mirabilis Infections.

Authors

Isabel Machuca, Juan J Pineda, Juan A Marín-Sanz, Cristina Riazzo, Julia Guzmán-Puche, Ángela Cano, Raquel Moya-Riballo, Noelia De la Torre-Capitán, Carmen Bermúdez, Jorge Rodríguez, Juan J Castón, Elena Pérez-Nadales, Nicolas Kieffer, Irene Gracia-Ahufinger, Elisa Ruiz-Arabi, Isabel Carmona, Lorena Pozo, Patricia Cosano, Andrés Baumela, Carmen de la Fuente, Luis Martínez-Martínez, Julián Torre-Cisneros

Published in

Infectious diseases and therapy. Oct 06, 2026. Epub Oct 06, 2026.

Abstract

OXA-48/extended-spectrum β-lactamase (ESBL)-producing Proteus mirabilis may appear susceptible to carbapenems in routine testing, potentially resulting in inappropriate therapeutic decisions. We aimed to evaluate clinical outcomes and the association between antimicrobial therapy and mortality.
We conducted a single-center observational study including 1254 patients with P. mirabilis infections (2017-2024). Seventy-nine OXA-48/ESBL cases (6.3%) were matched 2:1 with non-OXA-48/ESBL controls based on age, comorbidity, infection source, and severity. OXA-48 production was detected using the NG-Test CARBA 5 immunochromatographic assay, while ESBL production was inferred phenotypically using cefotaxime, ceftazidime, and cefepime discs alone and in combination with clavulanic acid. Predictors of 30-day mortality were assessed using time-dependent Cox regression models.
OXA-48/ESBL-producing infections were associated with higher 30-day mortality (absolute difference 19.7%; population attributable fraction 18.2%). Differences in mortality emerged after day 8, suggesting delayed clinical deterioration. In time-dependent models, OXA-48/ESBL status was not associated with early mortality (days 0-7) but strongly predicted late mortality [hazard ratio (HR) 14.5; 95% confidence interval (CI) 3.19-65.93; p = 0.001]. Among patients with OXA-48/ESBL infections, carbapenem-based regimens were associated with higher mortality than alternative active therapies (50% vs. 20%; p = 0.04), remaining significant after adjustment (HR 3.37; 95% CI 1.27-8.9), although residual confounding by indication cannot be excluded.
These observational findings support cautious interpretation of carbapenem susceptibility results and highlight the value of early carbapenemase detection to guide appropriate therapy. Graphical abstract available for this article.

PMID:
42836950
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.